JMP Securities Increases Durata Therapeutics Price Target to $14.00 (DRTX)
Equities research analysts at JMP Securities upped their price target on shares of Durata Therapeutics (NASDAQ:DRTX) from $12.00 to $14.00 in a research note issued to investors on Wednesday, AR Network reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ price objective indicates a potential upside of 48.46% from the stock’s previous close.
Shares of Durata Therapeutics (NASDAQ:DRTX) traded up 3.63% during mid-day trading on Wednesday, hitting $9.43. 178,573 shares of the company’s stock traded hands. Durata Therapeutics has a 1-year low of $6.65 and a 1-year high of $10.63. The stock’s 50-day moving average is $8.38 and its 200-day moving average is $7.89. The company’s market cap is $251.1 million.
Durata Therapeutics (NASDAQ:DRTX) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.52) by $0.23. On average, analysts predict that Durata Therapeutics will post $-2.73 earnings per share for the current fiscal year.
Separately, analysts at Wedbush cut their price target on shares of Durata Therapeutics (NASDAQ:DRTX) from $17.00 to $13.00 in a research note to investors on Friday, August 9th.
Three equities research analysts have rated the stock with a buy rating, Durata Therapeutics currently has an average rating of “Buy” and an average price target of $14.00.
Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.